Calidi Biotherapeutics Pioneers Next-Gen Cancer Therapies

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, has been featured in an editorial by NetworkNewsWire, titled "Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers." The article sheds light on Calidi's groundbreaking platform that employs engineered viruses to deliver genetic therapies directly to tumors, marking a significant advancement in the treatment of hard-to-treat cancers. Initially focusing on oncology, Calidi is also exploring applications in autoimmune disorders, showcasing its potential to revolutionize treatment across a spectrum of diseases. The editorial underscores Calidi's pivotal role in tackling the escalating global cancer crisis and pioneering innovative therapeutic solutions. For more details, the full press release can be accessed here.

Calidi Biotherapeutics stands at the forefront of immuno-oncology, with its proprietary technology designed to empower the immune system to combat cancer. Its novel stem cell-based platforms are capable of carrying oncolytic viruses, targeting high-grade gliomas and solid tumors, among other oncology indications. The company's off-the-shelf, universal cell-based delivery platforms aim to enhance the efficacy and safety of oncolytic viruses, offering hope for improved patient outcomes. Additionally, Calidi's preclinical enveloped virotherapies target disseminated solid tumors, potentially addressing or preventing metastatic disease. Headquartered in San Diego, California, Calidi Biotherapeutics is leading the charge in developing next-generation cancer therapies. Visit www.calidibio.com for more information.